Mercy Cell develops next-generation cell therapies using revolutionary chemically reprogrammed retinal progenitor cells (CiRPCs) to give hope back to millions living with blindness.
Three pillars that drive our mission to restore sight and transform lives through breakthrough cellular therapy technology.
CiRPCs technology generates retinal progenitor cells in just 5 days—unprecedented speed and efficiency in treating photoreceptor degeneration.
Addressing retinal diseases affecting 200+ million people worldwide, restoring dignity, independence, and opportunity to patients and families.
Leading the transformation from preserving vision to restoring it, with clear pathways from preclinical success to clinical reality.
Born from world-class research at Taiwan's Academia Sinica, Mercy Cell bridges the gap between groundbreaking science and life-changing treatments for patients with retinal diseases, ensuring that innovation reaches those who need it most.
Award-Winning Innovation
National Innovation Award • Future Technology Award
Academia Sinica Campus
Taiwan's Premier Research Institution
Taiwan's premier research institution provides the scientific foundation for our breakthrough CiRPCs technology, combining rigorous academic research with clinical application focus.
Compassionate Innovation
Tzu Chi Foundation Heritage
Grounded in compassion and ethical principles, our approach to cell therapy development reflects the humanitarian values that guide our mission.
Rooted in the compassion of Tzu Chi Charity Foundation, Mercy Cell explores innovative cell-based therapies for vision restoration, highlighting CiRPCs derived without the use of aborted fetal tissue, offering a safer and ethically sustainable alternative for treating retinal degeneration.
Ethical Cell Therapy
Sustainable • Compassionate • Safe
Partner with us to transform revolutionary science into life-changing treatments. Together, we can restore sight and transform lives across the globe.
Patient Success Stories
Vision Restoration Impact